Journal of Oncology Pharmacy Practice最新文献_第5页

Antineoplastic agents associated with neutropenic enterocolitis in patients with malignancy: A quantitative safety signal analysis. 与恶性肿瘤患者中性粒细胞减少性小肠结肠炎相关的抗肿瘤药物：定量安全信号分析。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-03-13 DOI: 10.1177/10781552241238195

Ali Amanati, Robbert Van Manen, Sarvin Sajedianfard, Hafez Shojaadini, Mohadese Boroughani, Hossein Molavi Vardanjani

{"title":"Antineoplastic agents associated with neutropenic enterocolitis in patients with malignancy: A quantitative safety signal analysis.","authors":"Ali Amanati, Robbert Van Manen, Sarvin Sajedianfard, Hafez Shojaadini, Mohadese Boroughani, Hossein Molavi Vardanjani","doi":"10.1177/10781552241238195","DOIUrl":"10.1177/10781552241238195","url":null,"abstract":"BackgroundThe use of certain chemotherapy agents is associated with the development of a condition called \"chemotherapy-associated neutropenic enterocolitis\" (CANE).ObjectiveTo determine the risk of CANE associated with the use of each antineoplastic agent.MethodsThe FDA FAERS database of spontaneous adverse reactions was searched for the occurrence of the MedDRA preferred term \"neutropenic colitis.\"ResultsThe search resulted in 1134 records of patients (535 [47.3%] females, 479 [42.2%] males, sex not specified in 120 [10.6%]) with neutropenic colitis receiving immunosuppressive chemotherapy. The mean age of patients was 47 (SD 22). 22 antineoplastic agents were found to have a strong association (reported odds ratio [ROR] > 100) with the occurrence of CANE; 9 had ROR < 2.ConclusionDrug databases have several limitations in providing updated information about newly approved pharmaceutical adverse events. Signal detection is a diagnostic method recognized as practical in pharmacovigilance. It may be utilized in the FDA's adverse event reporting database and has demonstrated a reasonable predictive performance in signaling adverse events. Our study emphasized the substantial knowledge gap between what we know about the potential risk of CANE caused by antineoplastic agents and the reports of the FDA on their new approved products.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"381-387"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140110531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nearly complete hair re-pigmentation in an older patient treated with hydroxyurea for essential thrombocytosis. 一名因血小板增多症接受羟基脲治疗的老年患者的头发几乎完全重新着色。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-09-23 DOI: 10.1177/10781552241285591

Shiva Salmasi, Ruba Alchaikh Hassan, Zahra Gafarzadeh, Constantin A Dasanu

{"title":"Nearly complete hair re-pigmentation in an older patient treated with hydroxyurea for essential thrombocytosis.","authors":"Shiva Salmasi, Ruba Alchaikh Hassan, Zahra Gafarzadeh, Constantin A Dasanu","doi":"10.1177/10781552241285591","DOIUrl":"10.1177/10781552241285591","url":null,"abstract":"IntroductionEmployed in the treatment of malignancies and non-neoplastic conditions, hydroxyurea is associated with integumentary adverse effects, including skin discoloration, xerosis, pruritus, cutaneous atrophy, chronic leg ulcers, oral ulcerations, alopecia, and some nail abnormalities.Case ReportA 77-year-old woman was diagnosed with essential thrombocytosis and started on low dose hydroxyurea. After 20 weeks of treatment, she experienced an unexpected change in hair color from gray to dark brown, without using hair dye or supplements. She later developed bilateral dorsal hand melanoderma, melanonychia, and onychodystrophy.Management and outcomeIt was decided to monitor the patient with no action taken as she was happy with this side effect of hydroxyurea. The platelet count has remained in excellent control. The dark brown hair color persisted over time.Discussion/ConclusionHair hyperpigmentation likely occurred through melanocyte activation via hydroxyurea. Severe side effects may require dosage adjustments, while milder effects can be monitored closely. The newly observed hair color restoration in this case highlights potential dual (therapeutic and aesthetic) applications of this class of agents.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"499-502"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Practical use of nadofaragene firadenovec-vncg for pharmacists. 纳法拉吉芬拉多韦在药师中的实际应用。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2025-02-17 DOI: 10.1177/10781552251315146

Seth D Holler, Sara Moran Smith

引用次数: 0

Identifying metrics and designing measurable outcomes in the electronic health record to evaluate pharmacist intervention in an oral chemotherapy program. 在电子健康记录中确定衡量标准并设计可衡量的结果，以评估药剂师在口服化疗计划中的干预。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-03-24 DOI: 10.1177/10781552241240439

Shelby Koppinger, Elizabeth Weil, Nichole Ruffcorn, Erin McGurty, Kevin Creal, Melissa Rhoades

{"title":"Identifying metrics and designing measurable outcomes in the electronic health record to evaluate pharmacist intervention in an oral chemotherapy program.","authors":"Shelby Koppinger, Elizabeth Weil, Nichole Ruffcorn, Erin McGurty, Kevin Creal, Melissa Rhoades","doi":"10.1177/10781552241240439","DOIUrl":"10.1177/10781552241240439","url":null,"abstract":"IntroductionDue to the increased utilization of oral anticancer agents, pharmacist-led oral anticancer programs have emerged to meet the needs of oral anticancer management. Currently, at Froedtert & MCW, there is a lack of established tools to collect metrics which demonstrate the value of a pharmacist-led oral anticancer program.MethodsThe purpose of this project is to establish metrics that reflect the interventions pharmacists are performing, and second, to develop a documentation tool which can reliably extract discrete data on the identified metrics.ResultsEight of the 10 desired metrics were included in the documentation tool. Two questionnaires were created to allow for easy data retrieval of the metrics. The \"initial\" questionnaire focuses on interventions made at the time of starting an oral anticancer agent, while the \"follow-up\" questionnaire focuses on interventions made during the subsequent monitoring. The introduction of the questionnaire tool was well received by end users and did not add to the pharmacist's overall workload.ConclusionsBy establishing metrics that reflect pharmacist interventions in a pharmacist-led oral anticancer program and creating a documentation tool to collect discrete data related to those metrics from the electronic health record, we at Froedtert & MCW are better able describe the workload of the ambulatory oncology pharmacists with regard to their interventions and monitoring of oral anticancer agents. This data will be used to establish differences in pharmacist workload between clinics, justify pharmacist resources, and provide a snapshot of the patient population served as part of the oral anticancer program.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"397-403"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140207139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Talimogene laherparepvec (T-VEC) as a treatment for melanoma: A systematic review. T-VEC治疗黑色素瘤：系统综述

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2025-01-17 DOI: 10.1177/10781552241312920

Sai Santhosha Mrudula Alla, Yogesh Tekuru, Moraboina Sai Lokesh, Deekshitha Alla, Patel Tvisha, Soujanya Tirupati, Aradhya Singh, Yeshala Tejaswini, Mariya Mahmood, Nanki Pratap Siingh, Bodipudi Vineetha

{"title":"Talimogene laherparepvec (T-VEC) as a treatment for melanoma: A systematic review.","authors":"Sai Santhosha Mrudula Alla, Yogesh Tekuru, Moraboina Sai Lokesh, Deekshitha Alla, Patel Tvisha, Soujanya Tirupati, Aradhya Singh, Yeshala Tejaswini, Mariya Mahmood, Nanki Pratap Siingh, Bodipudi Vineetha","doi":"10.1177/10781552241312920","DOIUrl":"10.1177/10781552241312920","url":null,"abstract":"Background and aimsMelanoma now presents an average risk of 1 in 50 in the Western world. Talimogene laherparepvec (T-VEC), an FDAapproved oncolytic virus derived from Herpes Simplex Virus type 1 (HSV-1), has proven effective in reducing morbidity and mortality from melanoma but causes adverse effects like chills, fever, exhaustion, and injection site discomfort. Research focuses on combining T-VEC with immune checkpoint inhibitors, such as pembrolizumab, to enhance its efficacy and broaden its application.MethodsA systematic search was conducted using PubMed, Scopus, Web of Science, Google Scholar, and ProMED, adhering to PRISMA guidelines. Results were tabulated and analyzed.ResultsThis review included 15 studies comprising nine cohorts, four case reports, a case series, and a randomized control trial, involving 779 melanoma patients in stages IIIB to IV, 58% of whom were male with a mean age of 65 years. Treatment duration with T-VEC averaged 35.07 weeks, with dosages ranging from 10^6 to 10^8 PFU/ml. The intervention yielded a mean DRR of 41.87% and an ORR of 62.2%. The most common side effect was chills, affecting 21.69% of participants. Pyrexia was reported by 20.41% of participants, followed by influenzalike illness (14.89%).ConclusionT-VEC effectively improves ORR and DRR in melanoma patients. However, further research is needed on combination therapy prospects and its adverse effects.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"481-487"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacist's role in the management of drug-drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients. 药剂师在处理 COVID-19 肿瘤科患者因尼马瑞韦/利托那韦引起的药物相互作用中的作用。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-03-07 DOI: 10.1177/10781552241237750

Carlos Guzmán Cordero, María Sáez-Torres de Vicente, Álvaro Jiménez Espinosa, Ana Isabel Gago Sánchez

{"title":"Pharmacist's role in the management of drug-drug interactions caused by nirmatrelvir/ritonavir in COVID-19 oncohematology patients.","authors":"Carlos Guzmán Cordero, María Sáez-Torres de Vicente, Álvaro Jiménez Espinosa, Ana Isabel Gago Sánchez","doi":"10.1177/10781552241237750","DOIUrl":"10.1177/10781552241237750","url":null,"abstract":"ObjectiveNew drugs developed for SARS-CoV-2 infection, such as nirmatrelvir/ritonavir (NMV/r), represent a potential for oncohematology patients, but also pose a challenge in managing the potential clinically relevant drug-drug interactions (pDDIs) that may arise. The aim of this study is to assess the frequency, severity, and pharmacist detection of pDDIs.MethodsThis prospective, observational, study spanned 8 months, involving 42 oncohematology patients prescribed NMV/r in a tertiary-level hospital. A Board Certified oncology pharmacist assessed pDDIs using three databases and made recommendations to prescribing physicians. Linear and logistic regression analyses were employed to explore the relationship between prescribed drugs and pDDIs.ResultsClinically relevant pDDIs were detected in 76.2% of patients, with 18.1% of all medications involved in drug-drug interactions (DDIs). The most common drugs implicated were atorvastatin and imatinib. Micromedex® identified 63.3% of interactions as major severity, while Lexicomp® and University of Liverpool classifications were less restrictive. Pharmacists prevented most DDIs from reaching patients through different interventions, including treatment monitoring (44.2%), discontinuation (36.5%), and dose reduction (17.3%).ConclusionThis study highlights the high prevalence of clinically significant pDDIs in oncohematology patients receiving NMV/r for COVID-19. Pharmacists, as integral members of the healthcare team, played a crucial role in detecting, categorizing, and mitigating these interactions. The results underscore the need for comprehensive studies to evaluate the impact of pharmacist-led interventions in optimizing drug therapy and enhancing patient safety in this vulnerable population.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"374-380"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140059677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recurrent, multisystem angioedema induced by 5-azacitidine. 5-氮杂胞苷诱发复发性多系统血管性水肿。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-10-04 DOI: 10.1177/10781552241288475

Ruba Alchaikh Hassan, Shiva Salmasi, Zahra Ghafarzadeh, Constantin A Dasanu

{"title":"Recurrent, multisystem angioedema induced by 5-azacitidine.","authors":"Ruba Alchaikh Hassan, Shiva Salmasi, Zahra Ghafarzadeh, Constantin A Dasanu","doi":"10.1177/10781552241288475","DOIUrl":"10.1177/10781552241288475","url":null,"abstract":"Introduction5-azacitidine is a hypomethylating agent (HMA) used for treating myelodysplastic syndrome (MDS) and certain myeloproliferative neoplasms (MPNs). Common side effects include myelosuppression, nausea and injection site reactions. Serious allergic reactions are rare with this class of agents.Case ReportWe describe a 71-year-old man with MDS/MPN who developed repeated episodes of angioedema after starting treatment with subcutaneous 5-azacitidine. Angioedema involved multiple body areas including the neck, genitalia, lower back and gastrointestinal system. Causality assessment linked this entity to 5-azacitidine via the Naranjo nomogram questionnaire, by scoring 9.Management and Outcome5-azacitidine was discontinued due to recurrent episodes of angioedema that occurred even after dose reduction. Steroids were helpful in terms of reversing this reaction. Afterwards, no further episodes of angioedema have been documented. The patient's thrombocytosis is currently well-controlled with low dose hydroxyurea.Discussion/ConclusionWe report herein a unique case of recurrent, multisystem angioedema likely related to 5-azacitidine. The exact mechanism of azacitidine-induced angioedema is not currently known. Symptoms, clinical findings and timing of presentation are not always clear-cut, and it may take more than one cycle of 5-azacitidine before the diagnosis is made. Supportive and symptomatic treatment will be provided based on the severity of the reaction. Future studies may offer more insights into the mechanism underlying this rare and serious, yet intriguing side effect.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"503-506"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142372081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral anticancer medicine interventions: A cross-sectional study in French community pharmacies. 口服抗癌药物干预：法国社区药房横断面研究。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-03-07 DOI: 10.1177/10781552241237743

Florent Macé, Christine Peyron, Amélie Cransac, Pauline Pistre, Mathieu Boulin

{"title":"Oral anticancer medicine interventions: A cross-sectional study in French community pharmacies.","authors":"Florent Macé, Christine Peyron, Amélie Cransac, Pauline Pistre, Mathieu Boulin","doi":"10.1177/10781552241237743","DOIUrl":"10.1177/10781552241237743","url":null,"abstract":"IntroductionThe increasing number of oral anticancer medicines (OAMs) dispensed in community pharmacies and the associated challenges (misuse, management of side effects) give the community pharmacist (CP) a major role in the pharmacotherapeutic management of cancer patients. In France, as a response to these challenges, cancer outpatients can schedule a meeting with their CP to ensure the safe and effective use of OAMs. The objectives of this study were to evaluate the perspectives of these interventions regarding their implementation and the opinion of French CPs.MethodsA declarative survey and semi-structured interviews were conducted with CPs that dispensed at least one OAM between January 2021 and March 2022. The study was conducted between April and August 2022.ResultsEighty-five CPs completed the survey. Of these pharmacists, 21% (n = 18) had already performed OAM interventions and 91% (n = 61) wanted to implement them. Lack of time, knowledge and training were the main barriers to implementation. No correlations were identified between the characteristics of community pharmacies and the likelihood of implementing OAM interventions.ConclusionsConsidering that CPs seem willing to implement them and the favourable context in France, this observational study highlights the potential of OAM interventions to improve the management of cancer patients. Though further studies are required to better evaluate the implementation and the potential effects of these interventions, OAM interventions could be relevant strategies in other healthcare systems to secure the management of cancer patients through the involvement of the CP.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"364-373"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140059676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ISOPP CAPhO Symposium 2025 Abstracts. ISOPP CAPhO研讨会2025摘要。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2025-04-03 DOI: 10.1177/10781552251320013

引用次数: 0

Innovation in hospital pharmacy: Modeling the installation of automated dispensing systems based on an oncology hospital experience transfer. 医院药房的创新：基于肿瘤医院经验转移的自动配药系统安装模型。

IF 1 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2025-04-01 Epub Date: 2024-03-21 DOI: 10.1177/10781552241239593

Soumaya El Baraka, Ali Cherif Chefchaouni, Aya Bourdaime, Oumaima Lahlou, Yassir El Alaoui, Younes Rahali

{"title":"Innovation in hospital pharmacy: Modeling the installation of automated dispensing systems based on an oncology hospital experience transfer.","authors":"Soumaya El Baraka, Ali Cherif Chefchaouni, Aya Bourdaime, Oumaima Lahlou, Yassir El Alaoui, Younes Rahali","doi":"10.1177/10781552241239593","DOIUrl":"10.1177/10781552241239593","url":null,"abstract":"ObjectiveThis study explores automated dispensing systems (ADS) implementation in hospitals, focusing on experience transfer between the National Institute of Oncology of Rabat (NIO) and the specialties hospital of Rabat (SHR) to develop a transferable ADS installation and management model.MethodA retrospective implementation and experience data analysis of 3 years ADS implementation at NIO and a prospective planification for SHR new implementation on 6 months were employed. Data collection included pharmacist team reports, personnel interviews, direct observations, and information system data exports. The study focused on identifying challenges a plan-do-check-act (PDCA) cycle.ResultsThe analysis revealed overestimation in ADS needs at NIO about 42%, leading to: Resource exhaustion; Challenges in timeline installation staff training and management, Disruptions in data integration and Incident Reports. These issues underscored the importance of a phased, well-planned implementation process.DiscussionThe study highlighted the crucial role of many comprehensive strategies. In accordance with the results of several studies, this work demonstrates the benefits of ADS in reducing medication errors and enhancing resource management, while also pointing out the necessity for accurate system sizing, effective integration with hospital information systems, and comprehensive staff training.ConclusionThe experience transfer between NIO and SHR provides a valuable model for ADS implementation in hospital pharmacies, proposing optimizations on: Implementation process; Timelines and mapping; Risk management and incident reports; Staff training, sensibilization and change control.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"388-396"},"PeriodicalIF":1.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140175145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0